Chemical Compound

Dacomitinib

CAS Registry Number 1110813-31-4
Dacomitinib chemical structure
Primary Record

Dacomitinib

In stock
2,973 g
Purity
99.2 %
CAS
1110813-31-4

Compound Identifiers & Properties

CAS
1110813-31-4
PubChem CID
11511120
SMILES
COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)NC(=O)/C=C/CN4CCCCC4
Canonical SMILES
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)/C=C/CN1CCCCC1

Names & Synonyms

  • Dacomitinib
  • 1110813-31-4
  • Vizimpro
  • dacomitinibum
  • Dacomitinib anhydrous
  • Dacomitinib [USAN]
  • Dacomitinib monohydrate
  • Dacomitinib (INN)
  • Dacomitinib (PF299804)
  • DACOMITINIB HYDRATE
  • PF-00299804
  • Dacomitinib (PF299804, PF299)
  • Dacomitinib (Standard)
  • Dacomitinib [USAN:INN]
  • PF299804
  • RefChem:585148
  • C24H25ClFN5O2
  • DACOMITINIB [INN]
  • D06XXH
  • UNII-2XJX250C20
  • Dacomitinib, PF299804
  • 2XJX250C20
  • MFCD19443734
  • SCHEMBL33147
  • DACOMITINIB [WHO-DD]
  • cc-194
  • MLS006011275
  • CHEBI:132268
  • DTXSID50149493
  • PF-299
  • pf00299804
  • GTPL7422
  • orb1305418
  • PF-299804
  • CHEMBL2110732
  • DTXCID8071984
  • PF-00299804 dacomitinib
  • SCHEMBL29354322
  • SCHEMBL29377735
  • CHEBI:91466
  • EX-A030
  • L01XE47
  • QCR-174
  • BDBM112499
  • Dacomitinib (PF-00299804)
  • GLXC-90191
  • HMS5081D15
  • PF299
  • AMY21292
  • AOB87383
  • AOB87735
  • BCP02530
  • EGFR Inhibitor PF-00299804
  • PF-00299804-03
  • ABP000126
  • EBC-24037
  • HY-13272R
  • NSC765888
  • NSC800084
  • PF-804
  • s2727
  • ZINC72266312
  • (E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
  • AKOS025401818
  • PF 00299804-03
  • ACN-031538
  • CCG-264987
  • CS-0500
  • DB11963
  • FD64992
  • NSC-765888
  • NSC-800084
  • RL00451
  • SDCCGSBI-0646934.P001
  • 1042385-75-0
  • CID11511120
  • US8623883, No. 2
  • NCGC00263185-09
  • NCGC00263185-10
  • AC-25915
  • AS-57686
  • BC261945
  • BP-43638
  • DA-56723
  • HY-13272
  • SC-94589
  • SMR004703025
  • PF299804|||PF299
  • AB0035896
  • (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
  • 5092U85G58
  • A8319
  • D5450
  • FT-0696499
  • NS00072953
  • SW219155-1
  • Y0338
  • J3.341.567B
  • PF 00299804
  • A11051
  • D09883
  • Dacomitinib (PF299804, PF-00299804)
  • PF-299804 (Dacomitinib PF-00299804)
  • Q-4059
  • EN300-7406881
  • PF-299804 (Dacomitinib,PF-00299804)?
  • A848337
  • A896262
  • (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
  • BRD-K57169635-001-04-5
  • Q17130597
  • (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
  • B0084-452473
  • 1110813-31-4 pound not PF 299804 pound not PF-299804
  • (2E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-PIPERIDIN-1-YLBUT-2-ENAMIDE
  • (2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
  • 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-
  • Dacomitinib, 98%, a potent irreversible ErbB inbibitor - 10MG 10mg
  • (E)-N-[4-(3-Chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidino-2-buteneamide
  • (2E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
  • (2E)-N-(4-(3-Chloro-4-fluorophenyl)amino)7-methoxyquinazolin-6-yl)4-(piperidin-1-yl)but-2-enamide monohydrate
  • (E)-N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-piperidin-1-ylbut-2-enamide
  • (E)-N-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide
  • (E)-N-[4-(3-chloro-4-fluoro-anilino)-7-methoxy-quinazolin-6-yl]-4-(1-piperidyl)but-2-enamide
  • (E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide,hydrate
  • (E)-N-[4-[(3-chloro-4-fluoro-phenyl)amino]-7-methoxy-quinazolin-6-yl]-4-(1-piperidyl)but-2-enamide
  • (E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
  • (E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
  • 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, hydrate (1:1), (2E)-
  • 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-
  • 2-Butenamide, N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-, (2E)-; (2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide; Dacomitinib; PF 00299804; PF 299; PF 299804